Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Thoracic 1

Conditions

Neoplasm Metastasis 3Recurrence 2Prostatic Neoplasms 2Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Nephrotic Syndrome 1Kidney Diseases 1Head and Neck Neoplasms 1Glioblastoma 1Gastrointestinal Diseases 1Familial Mediterranean Fever 1Fallopian Tube Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1Arthritis, Rheumatoid 1Amyloidosis 1All Solid Tumors 1

Interventions

Prednisone 103enzalutamide 76Docetaxel 72Abiraterone Acetate 68Leuprolide 47acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 45abiraterone 39apalutamide 29Prednisolone 27bicalutamide 26Zoledronic Acid 24radium Ra 223 dichloride 22pembrolizumab 22darolutamide 22Goserelin 22Triptorelin Pamoate 17cabazitaxel 16Androgen Antagonists 15sipuleucel-T 13luprolide acetate gel depot 12Injections 12Dexamethasone 12olaparib 11gallium 68 PSMA-11 10Mitoxantrone 10Pluvicto 9Ipilimumab 9Dutasteride 9Cyclophosphamide 9relugolix 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Prostatic Neoplasms × Pharmaceutical Preparations × Clear all
NCT00087854 2008-04-23

Study of Individualized Amonafide to Treat Prostate Cancer

Xanthus Pharmaceuticals, Inc.

Phase 1/2 Completed
40 enrolled
Genitourinary

Prostatic Neoplasms

NCT00285675 2006-05-31

Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004

Novacea

Phase 2 Unknown
25 enrolled
GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡